



French network of cooperative groups in oncology (GCO) at ASCO & EHA 2024 :

**13 oral communications, 19 posters
(selection)**



The GCO network is a French network of ten cooperative groups conducting clinical and translational research in France and in other countries on solid and liquid tumors (lung, digestive, gynecologic, lymphoma, leukemia, myeloma, head and neck, pediatric and brain cancers...).

They are all not-for-profit organizations and have been accredited as “French cooperative intergroup of international dimension in the field of cancer” by the French National Cancer Institute (INCa).

COLORECTAL AND NON-COLORECTAL CANCERS	2
GYNECOLOGIC CANCERS.....	2
LUNG CANCERS	3
BRAIN TUMORS.....	3
MALIGNANT HEMOPATHIES.....	4

COLORECTAL AND NON-COLORECTAL CANCERS

GERCOR : Groupe Coopérateur Multidisciplinaire en Oncologie
Multidisciplinary Oncology Cooperative Group

Oral communication – ASCO

[Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study.](#)

Romain Cohen

GYNECOLOGIC CANCERS

ARCAGY - Association de Recherche sur les Cancers dont GYNéologiques GINECO - Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens et du sein
Cooperative Gynecological Cancer Research Group

Oral communications – ASCO

[AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept \(AVB-S6-500\) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer](#)

Katherine Cynthia

[Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.](#)

Frederik Marmé

Poster session - ASCO

[Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301](#)

Luis Manso

[Consistent data about the predictive factors of the success of interval debulking surgery \(CC0-IDS\) in patients with advanced ovarian cancers in two large independent datasets](#)

Benoît You

[Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients \(pts\) with unresectable ovarian cancer \(OC\): Survival outcomes and immune correlates](#)

Alexandra Leary

[Phase 3 MIRASOL \(GOG 3045/ENGOT-ov55\) trial: Mirvetuximab soravtansine \(MIRV\) vs. investigator's choice chemotherapy \(ICC\) in older patients with platinum-resistant ovarian cancer \(PROC\) and high folate receptor-alpha \(FR \$\alpha\$ \) expression](#)

Diana Bello

[Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial](#)

Benoît You

[REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan \(R-DXd\) in patients with platinum resistant ovarian cancer \(OVC\)](#)

Isabelle Ray-Coquard

LUNG CANCERS

IFCT : Intergroupe Francophone de Cancérologie Thoracique
French Cooperative Thoracic Intergroup

Poster presentation – ASCO

[Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer \(NSCLC\) in the IFCT-1601 IONESCO phase 2 trial.](#)

Diane Damotte

NEURO ONCOLOGY

IGCNO-ANOCEF : InterGroupe Coopérateur de Neuro-Oncologie/Association des Neuro-OnCologues d'Expression Française
French neuro-oncology association

Oral communication – ASCO

[Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma](#)

Mehdi Touat

MALIGNANT HEMOPATHIES

FIM : French Intergroup of Myeloproliferative syndromes

FILO : French Innovative Leukemia Organization

ALFA : Acute Leukemia French Association

Poster presentations - EHA

[Multicenter retrospective observatory of acute myeloid leukemia patients with nup98 rearrangement. a study from the ALFA-FILO FRENCH AML INTERGROUP.](#)

Benoît Ducourneau

[Progression on covalent bruton tyrosine kinase inhibitors predicts poor outcomes in cbtki-exposed and cbtki-venetoclax double-exposed populations: A retrospective FILO STUDY IN 154 R/R chronic lymphocytic leukemia patients](#)

Loïc Ysebaert

[Minimal residual disease-guided combination of ibrutinib plus venetoclax compared to FCR in untreated patients with cll of intermediate risk : interim results from the phase ii filo trial.](#)

Anne-Sophie Michallet

[Wave study, a retrospective of FILO trial : patients with relapse waldenström's macroglobulinemia treated by venetoclax in real life](#)

Mathilde Vonfeld

IFM : Intergroupe Francophone du Myelome

Oral communication - ASCO

[All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.](#)

Cyrille Touzeau

[Phase 3 randomized study of isatuximab \(Isa\) plus lenalidomide and dexamethasone \(Rd\) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma \(NDMM TI\).](#)

Xavier P. Leleu

Oral communications – EHA

[Outcomes of patients with relapsed/refractory multiple myeloma following early progression after ide-cel therapy: an ifm study from the descar-t registry](#)

Cayla Sarah

[Randomized phase 3 study of isatuximab \(isa\) plus lenalidomide and dexamethasone \(rd\) with bortezomib \(v\) versus isard in patients with newly diagnosed transplant ineligible multiple myeloma \(NDMM TI\)](#)

Xavier Leleu

[Daratumumab \(dara\) + bortezomib/thalidomide/dexamethasone \(d-vtd\) followed by dara maintenance in transplant-eligible \(te\) newly diagnosed multiple myeloma \(ndmm\): >6-year update of cassiopeia](#)

Philippe Moreau

Poster presentations – EHA

[All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.](#)

Cyrille Touzeau

[Efficacy and safety of elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma \(RRMM\): results of the french compassionate use program on behalf of the IFM](#)

Mohamad Mohty

Publication only - EHA

[Treatment of newly diagnosed frail multiple myeloma patients with lenalidomide, cyclophosphamide and dexamethasone](#)

Maher Salamoon

LYSA : The LYmphoma Study Association

Oral communications – EHA

[Real-world assessment of anti-cd19 car-t cells in patients aged 75 years and older with relapsed or refractory large b cell lymphoma: a lysa study from the descar-t registry](#)

Blandine Guffroy

[Excellent outcome of patients with relapsed or refractory primary mediastinal b cell lymphoma treated with axicabtagene ciloleucel : a study from the french DESCART-t national registry](#)

Jean Galtier

[TRANSCAR : a real-life outcome study of relapsed/refractory transformed indolent non-hodgkin lymphoma in the context of car t-cells a descart analysis](#)

Pierre Stephan

[Outcomes of patients with relapsed/refractory multiple myeloma following early progression after ide-cel therapy: an IFM study from the DESCART-t registry](#)

Cayla Sarah

Posters - EHA

[Outcomes in patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide post-cd19-targeting CAR-t therapy: a LYSA study from the DESCART-t registry](#)

Vincent Camus

[Early pet evaluation at day 14 post axicabtagene ciloleucel infusion predicts outcome in large b-cell lymphoma: results from the alycante phase II study](#)

Yassine Al Tabaa

[Clinical characteristics, treatments, and outcomes of large b-cell lymphoma patients in third-line therapy included between 2018 and 2023 in the french prospective multicentric REALYSA cohort](#)

Caterina Cristinelli

[Clinical characteristics, treatment options and outcome of refractory and early relapse large b cell lymphoma \(LBCL\) patients included in the REALYSA cohort before CAR T cells era.](#)

Stephanie Guidez

[Deciphering the BCR repertoire via 5' RAPID amplification of CDNA ends \(5'RACE\) identifies primary mediastinal b-cell lymphoma cases with high tumor density and poorer outcomes](#)

Vincent Camus

- More information on the GCO network : www.gco-cancer.org

